Equities

CardioComm Solutions Inc

EKG:CVE

CardioComm Solutions Inc

Actions
Health CareMedical Equipment and Services
  • Price (CAD)0.01
  • Today's Change0.00 / 0.00%
  • Shares traded1.58m
  • 1 Year change0.00%
  • Beta-0.2950
Data delayed at least 15 minutes, as of Nov 15 2024 14:49 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CardioComm Solutions, Inc. is a global medical provider of consumer heart monitoring and medical electrocardiogram (ECG) software solutions. The Company’s technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. It develops advanced software, hardware and core laboratory reading services related to ECG and ambulatory arrhythmia monitoring systems for medical and consumer markets globally. Its Global ECG Management Solutions (GEMS) and GlobalCardio (Cloud based GEMS) products are licensed worldwide to hospitals, ECG commercial reading services and physicians. The Company is also engaged in manufacturing, marketing, and sales of personal ECG monitors direct to consumers. The products are marketed under the HeartCheck brand. It has developed compatibility of the HeartCheck device to its GEMS and GlobalCardio based software to enable use of the device for remote ECG/arrhythmia monitoring services.

  • Revenue in CAD (TTM)643.05k
  • Net income in CAD-141.08k
  • Incorporated1989
  • Employees16.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Verisante Technology Inc0.00-126.12k659.07k8.00---------0.0031-0.00310.00-0.0010.00-------460.04188.29-939.09--------------43.370.00-----107.53------
CardioComm Solutions Inc643.05k-141.08k1.93m16.00------3.00-0.0009-0.00090.0043-0.00351.621.283.63---35.58-56.56----92.0979.38-21.94-28.730.2911-9.29-----11.99-4.01-3,856.50---34.07--
ZoomMed Inc154.28k1.46m2.16m------1.4013.980.01070.01070.0011-0.001415.76--46.89--14,863.23----------943.16----------3,951.93--114.30------
EvokAI Creative Labs Inc0.00-13.65m2.28m-----------0.1467-0.14670.00-0.01050.00--0.3277---189.56-1,785.96-197.78-3,725.86-----------137.12---------3,520.74------
Binovi Technologies Corp-100.00bn-100.00bn2.31m0.00---------------0.0873-----------170.25---254.88--71.98---1,712.660.3215-------74.4213.94-79.12------
Data as of Nov 15 2024. Currency figures normalised to CardioComm Solutions Inc's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.